Mikaela Sekkidou

Mikaela Sekkidou

Auto-generated profile, based on publicly available information

Mikaela Sekkidou

Asthma and Allergy Center Limassol Cyprus

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2026 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
MSMikaela Sekkidou
Mikaela Sekkidou
EKEva Karglani
Eva Karglani
RPRouzha Pancheva
Rouzha Pancheva
PKParis Kantaras
Paris Kantaras
SPSimoneta Popova
Simoneta Popova
NNNicolaos Nicolaou
Nicolaos Nicolaou
Background: Evidence on the effectiveness of partially hydrolyzed formulas (pHF) as a nutritional intervention to prevent Allergic Manifestations (AM) is limited. Provided that not all pHF are the same in terms of allergenicity and immunogenicity, their role in reducing the risk of the Atopic March progression should be individually and longitudinally examined. Objective: To investigate whether the risk‐reduction effect of a specific pHF compared to a standard formula (SF) on Atopic Dermatitis (AD) within the first 6 months of life observed in the Allergy Reduction Trial (A.R.T.) persists at the age of 5 years and, if it applies to other AM. Methods: Parents/legal guardians of participants within the multicenter double‐blinded randomized controlled clinical Allergy Reduction Trial (A.R.T.) who constituted the Intention‐to‐Treat population set ( N = 551) were invited at the age of 5 years for an observational follow‐up, to answer an enriched validated questionnaire regarding doctor diagnosis of AM between 1 and 5 years of age, including AD, Food Allergy (FA), Asthma, and Allergic Rhinitis (AR). The prevalence and cumulative incidence of outcomes were calculated and Relative Risks, 95% Confidence Interval (RR, 95% CI) were estimated by Poisson Generalized Estimating Equations adjusted for study center, sex, family history of AD, family history of AR, family history of Asthma, and mode of delivery. Results: Four hundred and fifty‐five subjects (83%) completed the 5‐year follow‐up (pHF: 131/160, SF: 145/171 and EBF: 179/220). The RR from birth to 5 years was significantly lower in the pHF group, for the development of any AM [32.7% vs. 51.7%, RR 0.73 (0.57–0.94), p = .02], AD [22.1% vs. 38.5%, RR 0.58 (0.41–0.83), p = .003] and, FA [10.5% vs. 20.4%, RR 0.53 (0.29–0.95), p = .03] compared to the SF group. Infant feeding with the pHF resulted in 87% risk‐reduction of FA [1.5% vs. 12.4%, RR 0.13 (0.03–0.58), p = .007] between the ages of 1–5 years. Conclusion: In non‐exclusively breastfed infants at high‐risk for allergy, mixed‐feeding with a specific whey‐based pHF during the first 6 months of life may reduce the risk of atopic dermatitis and food allergy from birth up to the age of 5 years. However, further A.R.T. follow‐ups and other longitudinal studies with larger sample size are needed to provide additional evidence for the long‐term effectiveness of pHF in allergy prevention.

20 November 2025
Verified
Preprint
Open access
MSMikaela Sekkidou
Mikaela Sekkidou
EKEva Karglani
Eva Karglani
RPRouzha Pancheva
Rouzha Pancheva
PKParaskevas Kantaras
Paraskevas Kantaras
SPSimoneta Popova
Simoneta Popova
NNNicolaos Nicolaou
Nicolaos Nicolaou
Background : The role of partially hydrolyzed formulas (pHF) as a nutritional intervention for the prevention of Allergic Manifestations (AM) remains debatable, and the effectiveness of each specific pHF should be longitudinally examined. Objective : To investigate whether the risk-reduction effect of a specific pHF compared to a standard formula (SF) on Atopic Dermatitis (AD) within the first 6 months of life observed in the Allergy Reduction Trial (A.R.T.) persists at the age of 5 years and, if it applies to other AM. Methods : Parents/legal guardians of the A.R.T. participants who constituted the Intention-to-Treat population set (N=551) were invited to answer an enriched validated questionnaire regarding doctor diagnosis of AM between 1-5 years of age, including AD, Food Allergy (FA), Asthma, and Allergic Rhinitis. Results : Four hundred and fifty-five subjects (83%) completed the 5-year follow-up (pHF: 131/160, SF: 145/171 and EBF: 179/220). Infant feeding with the pHF resulted in 87% risk-reduction of FA [1,5% vs 12.4%, RR 0.13 (0.03-0.58), p=0.007] between the ages of 1-5 years compared to SF. The RR from birth to 5 years was significantly lower in the pHF group, for the development of any AM [32.7% vs 51.7%, RR 0.73 (0.57-0.94), p=0.02], AD [22.1% vs 38.5%, RR 0.58 (0.41-0.83), p=0.003] and, FA [10.5% vs 20.4%, RR 0.53 (0.29-0.95), p=0.03] compared to the SF group. Conclusion : In non-exclusively breastfed infants at high-risk for allergy, mixed-feeding with a specific whey-based pHF may reduce the risk of atopic dermatitis and food allergy from birth up to the age of 5 years.

24 July 2026 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
MSMikaela Sekkidou
Mikaela Sekkidou
PKParaskevas Kantaras
Paraskevas Kantaras
RPRouzha Pancheva
Rouzha Pancheva
YMYannis Manios
Yannis Manios
NNNicolaos Nicolaou
Nicolaos Nicolaou
TTthe A.R.T. Clinical Research Team
the A.R.T. Clinical Research Team